{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-25-000005","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2025-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.619404+00:00","generated_at":"2026-05-28T01:14:25.521020+00:00","sec_items":["2.02","7.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Amneal expects to meet or exceed 2024 full-year guidance; net leverage ~4x","bullets":["Expects to meet net revenue ($2.70-2.80B), adjusted EBITDA ($610-630M), and adjusted diluted EPS ($0.57-0.63).","Expects to exceed operating cash flow guidance ($280-320M) and capital expenditure guidance ($60-70M).","Estimates net leverage at approximately 4x as of December 31, 2024.","Guidance includes 100% of AvKARE EBITDA; adjusted EPS accounts for 35% non-controlling interest."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-25-000005","json":"https://secwatch.observer/filing/0001723128-25-000005.json","markdown":"https://secwatch.observer/filing/0001723128-25-000005.md","text":"https://secwatch.observer/filing/0001723128-25-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000005/0001723128-25-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000005/amrx-20250115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:14:25.521020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}